Amylin agonist peptides and uses therefor

Details Amylin agonist peptides and uses therefor Amylin agonist peptides and uses therefor

2007-09-18

2007-09-18

Epperson, Jon (Department: 1639)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C530S300000, C514S002600, C514S012200

Reexamination Certificate

active

10649138

ABSTRACT:
Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.

REFERENCES:
patent: 4743677 (1988-05-01), Noda et al.
patent: 4988512 (1991-01-01), Azria
patent: 4992530 (1991-02-01), Morita et al.
patent: 5112945 (1992-05-01), Westermark et al.
patent: 5116948 (1992-05-01), Westermark et al.
patent: 5124314 (1992-06-01), Cooper
patent: 5175145 (1992-12-01), Cooper
patent: 5234906 (1993-08-01), Young et al.
patent: 5266561 (1993-11-01), Cooper et al.
patent: 5281581 (1994-01-01), Cooper et al.
patent: 5298605 (1994-03-01), Westermark et al.
patent: 5321008 (1994-06-01), Beaumont et al.
patent: 5367052 (1994-11-01), Cooper et al.
patent: 5405831 (1995-04-01), MacIntyre et al.
patent: 5424221 (1995-06-01), Westermark et al.
patent: 5424394 (1995-06-01), Lehman De Gaeta et al.
patent: 5508260 (1996-04-01), Beaumont et al.
patent: 5527771 (1996-06-01), Beaumont et al.
patent: 5580953 (1996-12-01), Albrecht et al.
patent: 5641744 (1997-06-01), Cooper et al.
patent: 5656590 (1997-08-01), Rink et al.
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5814600 (1998-09-01), Rink et al.
patent: 5998367 (1999-12-01), Gaeta et al.
patent: 6114304 (2000-09-01), Kolterman et al.
patent: 6417164 (2002-07-01), Kolterman et al.
patent: 6610824 (2003-08-01), Gaeta et al.
patent: 2004/0097415 (2004-05-01), Kolterman et al.
patent: 0 309 100 (1989-03-01), None
patent: 0 408 294 (1990-07-01), None
patent: WO 89/06135 (1989-07-01), None
patent: WO 90/06936 (1990-06-01), None
patent: WO 92/11862 (1992-07-01), None
patent: WO 92/11863 (1992-07-01), None
patent: WO 92/15317 (1992-09-01), None
patent: WO 93/10146 (1993-05-01), None
Young, “Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozotocin diabetic rats” FEBS 1991, 287(1-2), 203-205.
Berge et al. “Pharmaceutical Salts” J. Pharm. Sci. 1997, 66(1), 1-16.
Sanke et al. “An Islet Mayloid Peptide is derived from an 89-amino acid precursor by proteolytic processing” J. Biol. Chem. 1988, 263(33), 17243-17246.
Bell, “Molecular Defects in Diabetes-Mellitus”,Diabetes, 40:413-422 (1991).
Betsholtz et al., “Islet Amyloid Polypeptide (IAPP): cDNA Cloning and Identification of an Amyloidogenic Region Associated with the Species-Specific Occurrence of Age-Related Diabetes Mellitus”,Experimental Cell Research, 183:484-493 (1989).
Betsholtz et al., “Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species”,FEBS Letters, 251:261-264 (1989).
Clark et al., “Islet Amyloid Formed From Diabetes-Associated Peptide May be Pathogenic in Type-2 Diabetes”,The Lancet, 2(8553):231-234 (1987).
Cooper et al., “Aylin and the amylin gene: strructure, function, and relationship to islet amyloid and to diabetes mellitus”,Biochem. Biophys, Acta., 1014:247-258 (1989).
Cooper et al., “The Amylin Superfamily: A Novel Grouping of Biologically Active Polypeptides Related to the Insulin A-Chain”,Prog. Growth Factor Research, 1:99-105 (1989).
Cooper et al., “Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients”,Proc. Natl. Acad. Sci., 84:8628-8632 (1987).
Cooper et al., “Amylin Found In Amyloid Deposits In Human Type 2 Diabetes Mellitus May Be A Hormone That Regulates Glycogen Metabolism In Skeletal Muscle”,Proc. Natl. Acad. Sci., 85:7763-7766 (1988).
Cooper et al., “Amylin and Non-Insulin-Dependent (Type 2) Diabetes Mellitis”,Diabetes 1988, ed. Larkins, R., Zimmet, P. & Chisholm, D. (Elsevier, Amsterdam), pp. 493-496 (1989).
Dayoff et al., “A Model off evolutionary Change in Proteins”,Atlas of Protein Sequences & Structure, vol. 5, pp. 89-99 (1972).
Deems et al., “Amylin of CGRP (8-37) Fragments Reverse Amylin-induced Inhibition of14C-Glycogen Accumulation”,Biochem. Biophys. Res. Commun., 181(1):116-120 (1991).
Doherty, “Endogenous Vasoactive Peptides”,Annual Reports in Medicinal Chemistry, 26:83-92 (1991).
Fujii et al., “Synthesis of Second Human Calcitonin Gene-Related Peptide (β-hCGRP) by Application of a New Disulfide-Bonding Reaction with Thallium(III) Trifuoroacetate”,Chem. Pharm. Bull., 35(12):4769-4776 (1987).
Fujii et al., “Syntheses of Cystine-Peptides by Oxidation of S-Protected Cysteine-Peptides with Thallium(III) Trifuoroacetate”,Chem. Pharm. Bull., 35(6):2339-2347 (1987).
Glenner et al., “Amyloid Fibrils Formed from a Segment of the Pancreatic Islet Amyloid Protein”,Biochem. Biophys. Res. Commun., 155(2):608-612 (1988).
Goodman and Gilman's “The Pharmacological Basis of Therapeutics”, Chapter 38 Pergamon Press, Eighth Edition (1990).
Gustavsson et al., “Normal Transthyretin and Synthetic Transthyretin-Fragments form Amyloid-Like Fibrils in Vitro”,Biochem. Biophys. Res. Commun., 175(3):1159-1164 (1991).
Hilbich et al., “Aggregation and Secondary Structure of Synthetic Amyloid .beta.A4 Peptides of Alzheimer's Disease”,J. Mol. Biol., 218:149-163 (1991).
Hiskey et al., “Sulfhydryl Group Protection in Peptide Synthesis”,The Peptides, vol. 3, Chapter 3, pp. 137-167 (1981).
Hubbard et al., “Soluiton strucutres of Calcitonin-gene-related-peptide analogues of calcitonin-gene-related-peptide and amylin”,Biochem. J., 275:785-788 (1991).
Johnson et al., “Islet Amyloid Polypeptide: Mechanisms of Amyloidogenesis in the Pancreatic Islets and Potential Roles in Diabetes Mellitus”,Laboratory Investigation, 66(5):522-535 (1992).
Johnson et al., “Factors Affecting Diabetogenesis and Amyloidogenesis are Provided by Studies of IAPP in the Dog and Cat”, In Natvig, J.B. et al., Editors, Amyloid and Amyloidogenesis, 1990. Norwall, Mass, Kluwer Academic Publishers, pp. 445-448 (1991).
Johnson et al., “Islet Amyoid, Islet-Amyloid Polypeptide, and Diabetes Mellitus”,New England Journal of Medicine, 321(8):513-518 (1989).
Johnson et al., “Newly Identified Pancreatic Protein Islet Amyloid Polypeptide”,Diabetes, 40:310-314 (1991).
Johnson et al., “Amyloid in the Pancreatic Islets of the Cougar (Felis Concolor) is derived from Islet Amyloid Polypeptide (IAPP)”,Comp. Biochem. Physiol., 98B(1):115-119 (1991).
Jordan et al., “Canine IAPP cDNA Sequence Provides Important Clues Regarding Diabetogenesis and Amyloidogenesis in Type 2 Diabetes”,Biochemical and Biophysical Research Communications, 169(2):502-508 (1990).
Leffert et al., “Rat amylin: Cloning and tissue-specific expression in pancreatic islets”,Proc. Natl. Acad. Sci. (PNAS), 86:3127-3130 (1989).
Leighton et al., “Pancreatic amylin and calcitonin gene-related peptide cause resitance to unsulin in skeletal muscle in vitro”,Nature, 335(6191):632-635 (1988).
Leighton et al., “Amlin inhibits glucose utilization in the soleus muscle of the rat in vitro”,Diabetologia, 31:513 A [Abstract 288] (1988).
Nishi et al., “Conservation of the sequence of islet amyloid polypeptide in five mammals is consistent with its putative role as an islet hormone”,Proc. Natl. Acad. Sci., 86:5738-5742 (1989).
O'Brien et al., “Islet Amyloid Polypeptide and Insulin Secretion from Isolated Perfused Pancreas of Fed, Fasted, Glucose-Treated, and Dexamethasone-Treated Rats”,Diabetes, 40:1701-1706 (1991).
Ohagi et al., “Sequence of islet amyloid polypeptide precursors of an old world monkey, the pig-tailed macaque (Macaca nemestrina), and the dog (Canis familaris)”,Diabetologia, 34:555-558 (1991).
Pettersson et al., “Calcitonin Gene-related Peptide: Occurrence in Pancreatic Islets in the Mouse and the Rat and Inhibition of Insulin Secretion in the Mouse”,Endocrinology

Affiliated with

Also associated with

Rating

Amylin agonist peptides and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amylin agonist peptides and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amylin agonist peptides and uses therefor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3803121